Projects per year
Personal profile
Education
- 2002 PhD, Department of Physiology, University of Oxford
Experience
- Attending Physician, Department of Obstetrics and Gynecology, National Cheng Kung University Hospital (1998/08~present)
- Elected Visiting Fellow, Corpus Christi College, Oxford, United Kingdom (2011~2012)
- Distinguished Professor, Departments of Pharmacology, Obstetrics and Gynecology, College of Medicine, National Cheng Kung University (2011/08~present)
- Associate Dean for Research, College of Medicine, National Cheng Kung University (2013~2019)
- Chairman, Department of Pharmacology, National Cheng Kung University (2014~2017)
- Coordinator, Pharmacology, Toxicology, Medicinal Biochemistry & Molecular Biology, National Science and Technology Council (2015~2016)
- Deputy Superintendent, National Cheng Kung University Hospital (2016~2019)
- Superintendent, National Cheng Kung University Hospital (2019~2022)
- President, National Cheng Kung University (2023/02~present)
Research Interests
- Genomic medicine
- Drug development
- Molecular biology
- Cellular physiology
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Meng-Ru Shen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
-
藉由巨量生物資訊分析方式整合臨床與基因體大數據以訂定高危險群大腸癌患者治療策略( IV )
Shen, M.-R. (PI)
22-01-01 → 22-12-31
Project: Research project
-
藉由巨量生物資訊分析方式整合臨床與基因體大數據以訂定高危險群大腸癌患者治療策略( III )
Shen, M.-R. (PI)
21-01-01 → 21-12-31
Project: Research project
-
-
藉由巨量生物資訊分析方式整合臨床與基因體大數據以訂定高危險群大腸癌患者治療策略( II )
Shen, M.-R. (PI)
20-01-01 → 20-12-31
Project: Research project
-
BDNFVal66Met protects oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer
Chen, L.-H., Lin, P. C., Yeh, Y.-M., Li, C. I., Chang, L. Y., Chang, J. Y. & Shen, M. R., 2026 Feb 18, In: Science translational medicine. 18, 837, eadx1436.Research output: Contribution to journal › Article › peer-review
-
Clinical and immunological implications of lymphocyte-activation gene 3 expression in metastatic colorectal cancer
Huang, Y. H., Wu, S. Y., Lee, C. T., Chung, B. S., Lin, P. C., Chan, R. H., Chen, P. C., Lin, B. W., Shen, M. R., Chen, S. H. & Yeh, Y. M., 2026 Apr, In: Cancer Immunology, Immunotherapy. 75, 4, 93.Research output: Contribution to journal › Article › peer-review
Open Access -
Artificial intelligence-driven body composition analysis enhances chemotherapy toxicity prediction in colorectal cancer
Liu, Y. Z., Su, P. F., Tai, A. S., Shen, M. R. & Tsai, Y. S., 2025 Oct, In: Clinical Nutrition ESPEN. 69, p. 696-702 7 p.Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Citation (Scopus) -
The RASAL2 variant promotes aberrant RAS signaling and resistance to anti-EGFR therapy in colorectal cancer
Yeh, Y. M., Hsu, Y. H., Huang, Y. T., Lin, P. C., Hsu, Y. T., Wu, P. Y. & Shen, M. R., 2025 Dec, In: Scientific reports. 15, 1, 31076.Research output: Contribution to journal › Article › peer-review
Open Access -
Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer
Chang, Y. C., Chen, S. J., Chen, S. H., Hsiao, S. Y., Chen, L.-H., Chen, C. H., Liu, C. C., Chen, Y. W., Liu, K. J., Wu, S. Y., Chu, J. M., Qiu, L. Y., Chiang, W. F., Hsieh, H. P., Hsueh, W. Y., Hsiao, J. R., Shen, M. R., Chang, J. Y. & Chang, K. Y., 2025 Dec, In: Journal of biomedical science. 32, 1, 69.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Citations (Scopus)